Myocardial infarction (MI) due to ischemic heart disease causes loss of cardiomyocytes, formation of scar in the infarcted region and progressive left ventricular dysfunction due to adverse remodeling. Angiotensin converting enzyme (ACE) inhibitors have been proven to improve prognosis in post-MI patients by attenuating remodeling. Nutraceuticals may be complementary with heart failure therapies as dietary modification has been proven beneficial in cardiovascular diseases. Resveratrol is a polyphenol which has been reported to afford cardiovascular benefits including antioxidant, antiinflammatory, and antifibrotic effects. Accordingly, we investigated the effect of a combination of resveratrol and perindopril (ACE inhibitor) on MI induced rats. MI was induced by ligating the left anterior descending artery (LAD) of male Sprague Dawley rats (175-200 g) and sham rats served as control. Sham and MI rats were treated with vehicle (50% ethanol), resveratrol alone, perindopril alone, or a combination of both (2.5 mg/kg body weight/day) by gavage for 8 weeks. Echocardiography was performed at baseline and 8 weeks. Measurements included fractional shortening (FS), left ventricular ejection fraction (LVEF), interventricular septal wall thickness (IVS), left ventricular posterior wall thickness (LVPW), and left ventricular internal dimension (LVID). Malondialdehyde (a marker of oxidative stress) levels were also measured in serum and heart tissue from all groups. At 8 weeks, MI control rats had a significantly lower LVEF compared to sham control rats (59.83±1.66 vs 77.38±1.42%, p<0.001). Notably, MI rats treated with resveratrol or perindopril alone had improved LVEF in comparison to MI control rats (59.83±1.66 vs 68.97±2.09 and 68.36± 2.58%, p<0.01). Also, MI rats treated with a combination of resveratrol and perindopril showed improved LVEF compared to MI control group (59.83±1.66 vs 66.33±1.68%, p<0.05). MI control rats also showed a significant increase in LV dilatation (LVID) (9.01±0.16 vs 10.60±0.30, p<0.001); resveratrol, perindopril alone or in combination with resveratrol significantly prevented LV dilatation compared to MI control rats (10.60±0.30 vs 9.47±0.30, 9.54±0.18, 9.45±0.17, p<0.01). FS, IVS and LVPW were unaltered in animals from all treatment groups. Furthermore, MI control rats had elevated level of malondialdehyde and treatment with resveratrol, perindopril alone or in combination was effective in significantly reducing the malondialdehyde level. Treatment with resveratrol or perindopril was equivalent in significantly improving cardiac structure and function in MI rats and a combination treatment also attenuated cardiac abnormalities, partly through reducing oxidative stress. Translation of these findings to clinical ischemic heart failure patients should be explored in future clinical trials.